Schrödinger to Announce Second Quarter 2025 Financial Results on August 6
The live webcast can be accessed in the 'Investors' section of Schrödinger's website and will be archived for approximately 90 days following the event.
About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 minutes ago
- Globe and Mail
AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical trial titled A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. The study aims to assess the safety and tolerability of the drugs AZD2284, AZD2287, and AZD2275 in treating this aggressive form of prostate cancer. The trial is testing three drugs: AZD2284, AZD2287, and AZD2275, all administered via intravenous methods. AZD2284 is the primary focus, with the goal of determining its optimal dosing and efficacy in conjunction with the other two drugs. This non-randomized, open-label study follows a sequential intervention model. It is primarily focused on treatment, with no masking involved, allowing for direct observation of the drug effects. The study began on March 10, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they indicate the study's progress and the timeline for potential results. This study's update could influence AstraZeneca's stock performance positively, as successful results may enhance investor confidence and market position in the oncology sector. Competitors in the prostate cancer treatment market will be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.
Globe and Mail
2 minutes ago
- Globe and Mail
Prediction: Nvidia Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Key Points Nvidia has the most powerful computer chips, and the major AI developers rely on them to drive their businesses. The total AI opportunity is expected to increase at a high rate over the next five years. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has been that rare stock that has catapulted investors to millionaire status on its own. But up more than 1,500% over the past five years, and with a $4 trillion market cap, can it really still offer growth for investors? It can. Here's why. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The age of AI All signs are that artificial intelligence (AI) will continue to drive innovation over the next few years as more businesses see how it can help them succeed and grow. As there's greater development in AI, it becomes cheaper and more abundant, and companies that aren't using it to become more efficient and user-friendly are losing out. Nvidia is the leader in the graphics processing units (GPU) that power these trends, with an overwhelming amount of market share. The AI market is growing at a fast pace, and the major players, like Amazon and Microsoft, need Nvidia's powerful chips to drive their efforts. Even companies like Amazon that are creating their own chips to offer more budget-conscious options still partner with Nvidia for their larger clients' needs. According to Statista, the AI market is expected to increase at a compound annual growth rate (CAGR) of 26.6% over the next five years. That's slower than Nvidia's current revenue growth. If you can imagine Nvidia keeping up such a CAGR for its own sales, keeping its price-to-sales ratio constant, that would lead to its stock price nearly tripling. Even if the price-to-sales ratio decreases, there could be some serious gains ahead for Nvidia investors over the next five years and beyond. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
CTV News
2 minutes ago
- CTV News
Company involved in Coldplay KissCam drama hires Gwyneth Paltrow as spokesperson
Gwyneth Paltrow arrives at the 11th Breakthrough Prize Ceremony on Saturday, April 5, 2025, in Los Angeles. (Photo by Jordan Strauss/Invision/AP, File) BOSTON — Astronomer — the company whose CEO resigned after being caught on a KissCam at a Coldplay rock concert embracing a woman who was not his wife — is trying to move on from the drama with someone who knows the band pretty well. Actress Gwyneth Paltrow, who was married to Coldplay's frontman Chris Martin for 13 years, announced Friday on X that she has been hired by Astronomer as a spokesperson. Astronomer, a tech company based in New York, found itself in an uncomfortable spotlight when two of its executives were caught on camera in an intimate embrace at a Coldplay concert — a moment that was then flashed on a giant screen in the stadium. CEO Andy Byron and human resource executive Kristin Cabot were caught by surprise when Martin asked the cameras to scan the crowd during a concert earlier this month. 'Either they're having an affair or they're just very shy,' Martin joked when the couple appeared on screen and quickly tried to hide their faces. In a short video, the 'Shakespeare in Love' and 'Ironman' star said she had been hired as a 'very temporary' spokesperson for Astronomer. 'Astronomer has gotten a lot of questions over the last few days and they wanted me to answer the most common ones,' Paltrow said, smiling and deftly avoiding mention of the KissCam fuss. 'We've been thrilled that so many people have a newfound interest in data workflow automation,' she said. 'We will now be returning to what we do best — delivering game-changing results for our customers.' When footage from the KissCam first spread online, it wasn't immediately clear who the couple were. Soon after the company identified the pair, and Byron resigned followed by Cabot. The video clip resulted in a steady stream of memes, parody videos and screenshots of the pair's shocked faces filling social media feeds. Online streams of Coldplay's songs jumped 20 per cent in the days after the video went viral, according to Luminate, an industry data and analytics company.
